# Plasmodium Immunotherapy for Breast and Liver Cancers

> **NCT03474822** · PHASE1,PHASE2 · RECRUITING · sponsor: **CAS Lamvac Biotech Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Advanced Breast Cancer
- Advanced Liver Cancer

## Interventions

- **BIOLOGICAL:** Blood-stage infection of P.vivax

## Key facts

- **NCT ID:** NCT03474822
- **Lead sponsor:** CAS Lamvac Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-08-10
- **Primary completion:** 2023-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03474822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03474822, "Plasmodium Immunotherapy for Breast and Liver Cancers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03474822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*